Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECCE-Expanded TIL in Metastatic Melanoma
NCT01369875Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2011
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by National Cancer Institute. Started Jun 2011; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01369875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369875.